Biomarkers in medicine / / edited by Pinar Atukeren and Hafize Uzun

• Autore: Atukeren Pınar
• Pubblicazione: Singapore : , : Bentham Science Publishers Pte. Ltd., , [2022]; ©2022
• Edizione: 1st ed.
• Descrizione fisica: 1 online resource (739 pages)
• Disciplina: 610.28
• Soggetto topico: Biomedical engineering; Radiology; Biomarkers; Biomarkers, Tumor
• Soggetto non controllato: Biochemical Markers; Clinical Biochemistry; Science; Medical
• Persona (resp. second.): AtukerenPinar; UzunHafize
• Nota di bibliografia: Includes bibliographical references.
• Nota di contenuto: Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- New Biomarkers and Immunotherapy Decision -- Abdurrahman Yigit1, Berkay Kuscu2, Ali Kirik2, Ruhsen Ozcaglayan2 and Cigdem Usul Afsar3,* -- NEW BIOMARKERS AND IMMUNOTHERAPY DECISION -- Principles of Cancer İmmunotherapy -- Tumor Immunology -- Therapeutic Approaches -- Immune Checkpoint Inhibitors (ICI) -- THE PREDICTIVE AND PROGNOSTIC MARKERS OF IMMUNOTHERAPY -- Immunotherapy Toxicity -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Gynecologic Tumors -- Selim Afsar1,* -- INTRODUCTION -- Ovarian and Fallopian Tube Cancers -- Carbohydrate Antigen 125 (CA125) -- Screening -- Prediction Models -- Prognosis -- Recurrence -- Human Epididymis Protein 4 (HE4) -- Diagnosis -- Prognosis -- Risk of Ovarian Malignancy Algorithm (ROMA) -- Circulating Cell-Free DNA (cfDNA) -- DNA Methylation -- Metabolites -- MicroRNAs -- Carcinoembryonic Antigen (CEA) -- Alpha-Fetoprotein (AFP) -- Inhibin B -- Human Chorionic Gonadotropin (hCG) -- Kallikreins -- Other Markers -- Uterine Cancer -- CA125 -- HE4 -- Genomic Classification -- Other Markers -- Cervical Cancer -- Squamous Cell Carcinoma Antigen (SCC-Ag) -- Other Markers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Biomarkers in Urological Cancers -- Bulent Onal1,*, Mehmet Hamza Gultekin1, Muhammed Fatih Simsekoglu1, Berin Selcuk1 and Ahmet Gurbuz1 -- BIOMARKERS IN BLADDER CANCER -- Blood-based Biomarkers -- Tumor Cells -- CD8 Count and Immune Cells -- Matrix Metalloproteinase -- Epigenetic Markers -- Tissue-based Biomarkers -- Cell Cycle-based Markers -- Transmembrane- and Signaling-based Markers -- PDL/PDL1 -- mTOR -- MDR1 -- Human Epidermal Growth Factor Receptor 2 (HER2). ; Apoptosis- and DNA Repair-Based Markers -- Multiplexed Markers -- Twenty-Gene Panel, GenomeDX Gene-Expression Assay -- Urine-based Biomarkers -- Fluorescence In situ Hybridization (FISH) -- Bladder Tumor Antigen (BTA) Tests -- Nuclear Matrix Protein-22 (NMP-22) Test -- ImmunoCyt Test -- CxBladder Test -- SUMMARY -- BIOMARKERS IN PROSTATE CANCER -- Blood-Based Biomarkers -- PSA or hK3 -- Free PSA (fPSA) -- Prostate Health Index (PHI) -- 4Kscore Test -- Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) -- Prostate-Specific Membrane Antigen (PSMA) -- Urine-Based Biomarkers -- PCA3 -- Gene Fusion -- SelectMDx -- Annexin A3 -- Tissue-Based Biomarkers -- α-Methylacyl Coenzyme A Racemase (AMACR) -- Epigenetic Modifications -- Genomic Expression Profiles -- Inherited Genetic Markers -- SUMMARY -- BIOMARKERS IN RENAL CELL CARCINOMA -- Diagnostic Biomarkers -- Carbonic Anhydrase IX (CAIX) -- Gene Expression Profile -- Urine Biomarkers -- Tissue Biomarkers -- Prognostic Biomarkers -- Routine Blood Biomarkers -- Von Hippel-Lindau (VHL) Gene -- VEGF -- Survivin -- p53 -- Ki-67 -- Phosphatase and Tensin Homolog (PTEN) -- Predictive Biomarkers -- Immune Checkpoint Inhibitors -- mTOR Inhibitors -- Pediatric Renal Tumors: -- SUMMARY -- BIOMARKERS IN TESTICULAR CANCER -- Alfa-fetoprotein (AFP) -- Human Chorionic Gonodotropin (HCG) -- Lactate Dehydrogenase (LDH) -- Potential Biomarkers in Future -- Placental Alkaline Phosphatase (PLAP) -- Oct-3/4, Sall 4, and CD 117 -- miRNAs -- SUMMARY -- NEXT GENERATION SEQUENCING -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Thyroid Cancer -- Lebriz Uslu-Beşli1,* -- INTRODUCTION -- THYROID GLAND -- CLASSIFICATION OF THYROID CANCER -- MEDICAL MANAGEMENT OF THYROID CANCER -- Differentiated Thyroid Cancer -- Medullary Thyroid Cancer. ; Anaplastic Thyroid Cancer -- SEROLOGICAL BIOMARKERS -- Thyroglobulin -- Anti-thyroglobulin Antibodies -- Calcitonin and Procalcitonin -- Carcinoembryonic Antigen -- Other Peptides -- LIQUID BIOPSY -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- DNA Methylation Biomarkers in Cancer: Current Clinical Utility and Future Perspectives -- Sinem Durmus1,*, Remise Gelisgen1 and Hafize Uzun2 -- INTRODUCTION -- DNA METHYLATION AND REGULATION MECHANISM -- DNA Methylation in Cancer -- Regional Hypermethylation -- Global Hypomethylation -- DNA Methylation Biomarkers in Cancer -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Circulating Biomarkers in Predicting Pathological Response to Neoadjuvant Therapy for Colorectal Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Tissue Based Biomarkers -- DNA Alterations: Polymorphisms -- Gene Expression -- MicroRNA (miRNA) -- Blood Based Biomarkers -- cfDNA and ctDNA -- cfmRNA and hTERT -- cfmiRNA -- CIRCULATING PROTEINS/PEPTIDES -- OTHER PREDICTIVE BIOMARKERS -- Thymidylate Synthase (TS) -- Epidermal Growth Factor Receptor (EGFR) -- Cyclooxygenase 2 (COX-2) -- Bax/bcl-2 -- P21 -- Ki-67 -- CEA -- ctDNA -- Circulating Tumour Cells (CTC) -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERANCES -- Circulating Biomarkers in the Management of Breast Cancer -- Ravindri Jayasinghe1, Umesh Jayarajah1,* and Sanjeewa Seneviratne1 -- INTRODUCTION -- ESTABLISHED BIOMARKERS -- Carcinoembryonic Antigen (CEA) -- MUC-1 -- HER-2 -- Cytokeratins (CK) -- Specific Classes of Circulatory Biomarkers -- Proteins -- Autoantibodies -- Circulating Tumour Cells (CTC) -- Exosomes -- MicroRNA (miRNA) -- Circulating Cell-Free DNA (cfDNA). ; BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS OF BREAST CANCER -- MONITORING RESPONSE TO THERAPY AND SURVEILLANCE -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Application of Biomarkers for Hematologic Malignancies -- Nurgül Özgür Yurttaş1 and Ahmet Emre Eşkazan1,* -- INTRODUCTION -- BIOMARKERS IN MYELOID NEOPLASMS -- Acute Myeloid Leukemia -- CYTOGENETIC CLASSIFICATION OF AML -- MRD IN AML -- Myelodysplastic Syndrome -- CHROMOSOMAL ABNORMALITIES IN MDS -- Deletions of Chromosome 5 -- Monosomy 7 and Deletions of Chromosome 7 -- Diagnosis and Classification -- 5q-syndrome/MDS with an Isolated del(5q) -- Role of Cytogenetics in the Prognosis of MDS -- GENETIC MUTATIONS IN MDS -- Myeloproliferative Neoplasms -- Mutations in PV, ET, and PMF -- BIOMARKERS IN CHRONIC MYELOID LEUKEMIA -- Prognostic Factors at the Time of Diagnosis -- Use of the Mutational Analysis in CML -- Identification of Molecular Markers of Progression -- BIOMARKERS IN LYMPHOID NEOPLASMS -- BIOMARKERS IN ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA -- CYTOGENETIC AND MOLECULAR ABNORMALITIES IN ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA -- B-ALL/LBL with Recurrent Genetic Abnormalities -- T-ALL/LBL -- Cytogenetic Abnormalities in T-ALL/LBL -- Molecular Abnormalities in T-ALL/LBL -- EARLY T-CELL PRECURSOR ALL/LBL -- MRD IN ALL -- BIOMARKERS IN LYMPHOMAS -- Biomarkers of Genetic Changes -- B-Cell Lymphoma 6 (BCL6) -- Tumor Protein 53 (TP53) -- V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC) -- B-Cell Lymphoma 2 (BCL2) -- Myeloid Differentiation Primary Response 88 (MYD88) -- Other Genetic Biomarkers in B-Cell Lymphomas -- Other Genetic Biomarkers in Peripheral T-Cell Lymphoma (PTCL) -- Biomarkers Related to Epigenetic Changes -- Other Epigenetic Gene Features -- MicroRNA and LncRNA in Diagnosis and Prognosis of Lymphomas. ; Other MicroRNAs and MicroRNA-Based Classifiers -- Immunophenotypic Biomarkers -- CD30 -- Bcl-6, Bcl-2, and Myc -- Cyclin D1 and SOX-11 -- TP53 and MDM2 -- Immunophenotypic Biomarkers -- Immunohistochemical Biomarkers of Peripheral T-Cell Lymphoma -- Microenvironment-related Biomarkers for Prognosis and Immunotherapy -- BIOMARKERS IN MULTIPLE MYELOMA -- STAGING SYSTEMS -- GENOMIC BIOMARKERS -- Gene Expression Profiling -- NOVEL BIOMARKERS -- Minimal Residual Disease -- Next-Generation Biomarkers in MM -- Immunotherapy-related Biomarkers -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Applications of Biomarkers in Cancer Surgery -- Berrin Papila Kundaktepe1,* -- INTRODUCTION -- CIRCULATING TUMOR MARKERS: CLINICAL APPLICATIONS -- Applications Of Tumor Markers In Colorectal Cancer -- Applications of Tumor Markers in Hepatocellular Carcinoma (HCC) -- Applications of Tumor Markers in Pancreatic Adenocarcinoma -- Applications of Tumor Markers In Breast Cancer -- Circulating Tumor Cells -- ENDOCRINE TUMOR MARKERS -- Immunohistochemical and Circulating Tumor Markers of NETs -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- A Pathophysiological Approach To Current Biomarkers -- Aykut Oruc1,* and Gonul Simsek1 -- CARDIAC BIOMARKERS -- Cardiac Troponins -- Troponin Subunits -- Regulatory Function of Troponin -- Cardiac Troponins as a Biomarker for Acute Myocardial Infarction: The Pathophysiology -- Cardiac Troponins as a Biomarker in Congestive Heart Failure -- Heart-Type Fatty Acid Binding Protein -- Heart-Type Fatty Acid Binding Protein in Acute Myocardial Ischemia -- Glycogen Phosphorylase Isoenzyme BB -- Myocardial Oxygen Deficiency and GPBB Release: The Pathophysiology -- Glutathione S-Transferase P1 -- N-Terminal pro-Brain Natriuretic Peptide. ; Pathophysiological Mechanisms in Synthesis and Secretion of BNP and NT-proBNP.
• Sommario/riassunto: Biomarkers in Medicine is a comprehensive guide to understanding the current and future status of biomarkers. The book features 27 chapters focusing on disease biomarkers for diseases such as cancer, neurodegenerative diseases, cardiac diseases, metabolic conditions and much more. This book supplies readers with the unique insight of experts in multiple specialties in medicine and life sciences who have extensive experience in diagnostics and clinical laboratories. The book includes case studies and practical examples from different classes of biomarkers on different platforms, including new data for biomarkers in different therapeutic indications. In addition to presenting biomarker information, each chapter covers the relevant pathology and also emphasizes on preclinical and clinical manifestation of the disease process. Clinicians managing patients or clinical trials, clinical researchers, clinical laboratories, diagnostic companies, regulatory agencies, medical school graduate students, academic students, and the general public involved in healthcare delivery will all benefit from information presented in this book.
• Titolo autorizzato: Biomarkers in medicine
• ISBN: 981-5040-46-4
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910819897803321
• Lo trovi qui: Univ. Federico II